Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK’s Ofatumumab and Pazopanib Granted Orphan Drug Designation
December 9, 2011
- Kyowa Kirin Aims to Make RNAi Drugs Future Pillar: Dr Shitara
December 9, 2011
- Kobayashi, President of Mitsubishi Chemical HD Expects Continuous Growth of Pharmaceutical Business
December 9, 2011
- Takeda Says FDA Committee Indicates Recommendation for Peginesatide
December 9, 2011
- Shionogi Announces Favorable Decision in Fortamet Preliminary Injunction Proceedings
December 9, 2011
- MTPC Sets Up External Committee to Promote Appropriate Use of Telavic
December 8, 2011
- Mebiopharm, Nawaloka HD to Establish Joint Venture in Sri Lanka
December 8, 2011
- Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
- Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
- FDA Accepts NDA for US BMS/US Pfizer’s Apixaban
December 7, 2011
- US Merck to Establish Asia R&D Headquarters in Beijing
December 7, 2011
- Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
- Samsung, Biogen Idec Agree to Set Up Biosimilar Joint Venture Company
December 7, 2011
- Ethical Drug Sales Up 7% in October; 6th Monthly Increase in a Row: Crecon
December 7, 2011
- AnGes MG Reaches Agreement with Japanese, Korean Companies to Develop Therapeutic CIN Vaccine
December 6, 2011
- US Sunovion to Resubmit NDA for Antiepileptic Treatment STEDESA
December 6, 2011
- Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
- US Consulting Firm Says New Forecast Will Be Necessary for Anticancer Drug Market
December 6, 2011
- Taiho to Cooperate in Doctor-Led Clinical Trial
December 6, 2011
- Takeda Sets Up Global Vaccine Business Company to Enhance Global Operations
December 6, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…